SUB-STANDARD DRUGSHC seeks DDA DG's explanation
The High Court finds non-compliance of its ruling by the Directorate of Drug Administration.
bdnews24.com News Service
bdnews24.com
Published :
03 May 2011, 02:33 PM
Updated :
10 Aug 2022, 04:45 PM
Dhaka, May 3 (bdnews24.com) — The High Court has told the director general (DG) of the Directorate of Drug Administration (DDA) to explain within two weeks why contempt of court proceedings should not be initiated against him.
The bench of justices Mohammad Ashfaqul Islam and M Moazzam Husain on Tuesday issued the rule against Abul Kalam Azad following a petition filed by Monzil Morshed on behalf of Human Rights and Peace for Bangladesh.
Morshed told reporters that since the High Court in January banned production and marketing of eight drugs, accordingly, DDA issued a notice.
"Later, Innova Pharmaceuticals Limited, producer of Diclofenac, appealed to review the High Court order. Though the court did not respond to the petition, the directorate withdrew its notice. As a result, the drug is still in the market," Morshed said.
In November last year, the High Court ordered the authorities concerned, including the health ministry, to submit within four weeks a report on 48 tests of 174 drugs.
The authorities found eight of the drugs sub-standard.
On Jan 27, the court ordered to stop production and marketing of the eight drugs and withdraw them from the market.
The other drugs were Tetracycline and Indox capsule of North Bengal Pharmaceuticals Ltd, BT Mox 500 milligram and BT Mox 250 milligram capsules of Bengal Techno Chemical Works Ltd, Indo Tetra of Indo Bangla Pharma, and Safox capsule and Tempil suspension of Alco Pharma Ltd.
bdnews24.com/sn/ost/nir/2014h